Revelation Biosciences Inc. Common Stock (REVB)

About REVB

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory res…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

8

Website

www.revbiosciences.com/

Fundamentals

1-day range

$1$1.06

Market cap

$3.99M

P/E (trailing)

0.04

P/E (forward)

-0.36

EPS (trailing)

$-17.64

Dividend yield

—

Beta

-0.06

Avg. volume

46.3K

Forecasts

2 analyst ratings

Revelation Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• REVB

  Revelation Biosciences Inc. Common Stock

  $1.05

  ▲ 1.94%
  Market cap $3.99MP/E 0.04
  $0.875$11.6
• RDHL

  Redhill Biopharma Ltd. American Depositary Shares

  $0.6899

  ▲ 9.51%
  Market cap $3.95MP/E —
  $0.57$2.79
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $4.02MP/E —
  $3.18$71.5
• MBIO

  Mustang Bio Inc. Common Stock

  $0.5375

  ▼ 2.27%
  Market cap $3.88MP/E —
  $0.525$1.85
• INM

  InMed Pharmaceuticals Inc. Common Shares

  $1.43

  ▼ 0.35%
  Market cap $4.09MP/E —
  $0.575$2.5
• ZSTK

  ZeroStack Corp. Common Stock

  $5.51

  ▼ 6.29%
  Market cap $4.21MP/E —
  $1.32$47
• XRTX

  XORTX Therapeutics Inc. Common Shares

  $2.34

  ▼ 4.18%
  Market cap $3.69MP/E —
  $2.42$9.85

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Thursday's After-Market Session
  Benzinga · 8/20/2026
• Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
  benzinga · 8/19/2026
• Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
  Benzinga · 8/19/2026
• Revelation Biosciences (NASDAQ:REVB) Surges on Pipeline Progress Despite Q2 Earnings Miss
  ChartMill · 8/6/2026
• Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
  Benzinga · 8/6/2026
• Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
  Benzinga · 8/3/2026

• Chester Stanley Zygmont III · April 30, 2026 · Tax Withholding

  13.3K @ $1.1
• James Rolke · April 30, 2026 · Tax Withholding

  10.1K @ $1.13

Institutional Ownership

March 31, 2026

Total shares held

486.5K

Total value held

$584.0K

Institutional holders

10